Drug Patents owned by Strongbridge

1. Drug name - RECORLEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835530 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions Jan, 2026

(3 years from now)

US10517868 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions Jan, 2026

(3 years from now)

US10098877 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions Jan, 2026

(3 years from now)

US9918984 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions Jan, 2026

(3 years from now)

US11020393 STRONGBRIDGE Methods of treating disease with levoketoconazole Mar, 2040

(17 years from now)

Drugs and Companies using LEVOKETOCONAZOLE ingredient

Treatment: Treatment of endogenous hypercortisolemia in patients with cushing’s syndrome for whom surgery is not an option or has not been curative; During levoketoconazole dosage titration for the treatment of cushing's syndrome in patients who concomitantly use metformin, monitoring glycemia, kidney function and vitamin b-12 and adjusting dosage of metformin as needed

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.